Denosumab in early breast cancer: negative data and a call to action
Mené dans 39 pays sur 4 509 patientes atteintes d'un cancer du sein de stade précoce, cet essai de phase III évalue l'efficacité, du point de vue de la survie sans métastase osseuse, et la toxicité du dénosumab en traitement adjuvant
In The Lancet Oncology, Robert Coleman and colleagues report that the addition to adjuvant therapy of an intensive treatment with denosumab (120 mg subcutaneously every 3–4 weeks and then every 12 weeks for 5 years) in the D-CARE trial does not improve clinically significant outcomes of patients with early breast cancer. Moreover, 122 (5%) of the 2241 patients receiving denosumab had osteonecrosis of the jaw, which had not resolved by data cutoff in more than half of the cases. (...)
The Lancet Oncology , commentaire, 2018